Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 7/20 | 0.56 |
| ▸ | ADRA2A | P08913 | 4/20 | 0.56 |
| ▸ | ADRA2B | P18089 | 3/20 | 0.56 |
| ▸ | ADRA2C | P18825 | 3/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | BRD4 | O60885 | 4/20 | 0.41 |
| ▸ | HTR2A | P28223 | 1/20 | 0.38 |
| ▸ | HTR2C | P28335 | 1/20 | 0.38 |
| ▸ | HTR2B | P41595 | 1/20 | 0.38 |
| ▸ | PGR | P06401 | 1/20 | 0.37 |
| ▸ | AR | P10275 | 1/20 | 0.37 |
| ▸ | CREBBP | Q92793 | 2/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | EP300 | Q09472 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30664953 | 1.00 | PNMT (0.56) | PNMTADRA2AADRA2BADRA2CLMNA | |
| SCHEMBL26656333 | 1.00 | PNMT (0.56) | PNMTADRA2AADRA2BADRA2CLMNA | |
| SCHEMBL30697867 | 0.86 | PNMT (0.62) | PNMTADRA2AADRA2BADRA2CHTR2A | |
| SCHEMBL17018035 | 0.81 | PNMT (0.45) | PNMTADRA2AADRA2BADRA2CLMNA | |
| SCHEMBL21172482 | 0.81 | PNMT (0.45) | PNMTADRA2AADRA2BADRA2CBRD4 | |
| SCHEMBL31511298 | 0.81 | PNMT (0.45) | PNMTADRA2AADRA2BADRA2CLMNA | |
| SCHEMBL30294039 | 0.81 | PNMT (0.45) | PNMTADRA2AADRA2BADRA2CLMNA | |
| SCHEMBL16585592 | 0.81 | PNMT (0.45) | PNMTADRA2AADRA2BADRA2CLMNA | |
| SCHEMBL12965849 | 0.79 | AR (0.45) | PNMTADRA2AADRA2BADRA2CLMNA | |
| SCHEMBL31188791 | 0.78 | PNMT (0.41) | PNMTADRA2AADRA2BADRA2CBRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12522582-B2 | Antiviral indolinyl compounds and uses thereof | GILEAD SCIENCES, INC. (US) | 2026-01-13 | — | — | US | disclosed |
| EP-4648853-A1 | TARGETED DEGRADATION OF VAV1 | Monte Rosa Therapeutics AG (CH) | 2025-11-19 | — | — | EP | disclosed |
| US-20250205219-A1 | TARGETED DEGRADATION OF VAV1 | MONTE ROSA THERAPEUTICS AG (CH) | 2025-06-26 | — | — | US | disclosed |
| EP-4526289-A1 | ANTIVIRAL INDOLINYL COMPOUNDS AND USES THEREOF | GILEAD SCIENCES, INC. (US) | 2025-03-26 | — | — | EP | disclosed |
| US-12257247-B2 | Targeted degradation of VAV1 | MONTE ROSA THERAPEUTICS AG (CH) | 2025-03-25 | — | — | US | disclosed |
| US-20240285604-A1 | TARGETED DEGRADATION OF VAV1 | MONTE ROSA THERAPEUTICS AG (CH) | 2024-08-29 | — | — | US | disclosed |
| WO-2024151547-A1 | TARGETED DEGRADATION OF VAV1 | MONTE ROSA THERAPEUTICS, INC. (US) | 2024-07-18 | — | — | WO | disclosed |
| US-20240101529-A1 | ANTIVIRAL INDOLINYL COMPOUNDS AND USES THEREOF | GILEAD SCIENCES, INC. | 2024-03-28 | — | — | US | disclosed |
| WO-2023225162-A1 | ANTIVIRAL INDOLINYL COMPOUNDS AND USES THEREOF | GILEAD SCIENCES, INC. (US) | 2023-11-23 | — | — | WO | disclosed |
| WO-2023019166-A1 | PROTEIN TYROSINE PHOSPHATASE TARGETING LIGANDS | CALICO LIFE SCIENCES LLC (US) | 2023-02-16 | — | — | WO | disclosed |
| EP-1060186-A1 | 20-KETO-11BETA-ARYLSTEROIDS AND THEIR DERIVATIVES HAVING AGONIST OR ANTAGONIST HORMONAL PROPERTIES | RESEARCH TRIANGLE INSTITUTE (US) | 2000-12-20 | — | — | EP | disclosed |
| WO-1999045022-A1 | 20-KETO-11β-ARYLSTEROIDS AND THEIR DERIVATIVES HAVING AGONIST OR ANTAGONIST HORMONAL PROPERTIES | RESEARCH TRIANGLE INSTITUTE (US) | 1999-09-10 | — | — | WO | disclosed |
| CN-1021445-C | PROCESS FOR PREPARATION OF STEROIDS INCLUDING A SPIRO RING IN POSITION 17 | ROUSSEL UCLAF (FR) | 1993-06-30 | — | — | CN | disclosed |
| EP-0262188-B1 | STEROIDS COMPRISING A SPIRANIC CYCLE IN POSITION 17, PREPARATION PROCESS AND UTILIZATION THEREOF | ROUSSEL-UCLAF (FR) | 1990-11-14 | — | — | EP | disclosed |
| US-4900725-A | CONTRACEPTIVES | ROUSSEL UCLAF (FR) | 1990-02-13 | — | — | US | disclosed |
| EP-0262188-A1 | STEROIDS COMPRISING A SPIRANIC CYCLE IN POSITION 17, PREPARATION PROCESS AND UTILIZATION THEREOF. | ROUSSEL UCLAF (FR) | 1988-04-06 | — | — | EP | disclosed |
| CN-87103193-A | Steroid compounds containing a spiro ring in position 17, process and intermediates for their production, their use as medicaments and pharmaceutical compositions containing them | — | 1988-01-13 | — | — | CN | disclosed |
| WO-1987005908-A1 | STEROIDS COMPRISING A SPIRANIC CYCLE IN POSITION 17, PREPARATION PROCESS AND UTILIZATION THEREOF | ROUSSEL-UCLAF (FR) | 1987-10-08 | — | — | WO | disclosed |
| EP-0002721-B1 | PROCESS FOR PREPARING HYDRAZINES | BAYER AG (DE) | 1981-09-02 | — | — | EP | disclosed |
| EP-0002721-A2 | Process for preparing hydrazines | BAYER AG (DE) | 1979-07-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240101529-A1 | ANTIVIRAL INDOLINYL COMPOUNDS AND USES THEREOF | MAVS, IRF3, EIF2AK2 | PNMT 509/4885ADRA2A 4565/4885ADRA2B 4660/4885 |
| US-20240285604-A1 | TARGETED DEGRADATION OF VAV1 | VAV1, KRAS, CBL | PNMT 4106/4885ADRA2A 3731/4885ADRA2B 4004/4885 |
| US-12257247-B2 | Targeted degradation of VAV1 | VAV1, KRAS, CBL | PNMT 4106/4885ADRA2A 3731/4885ADRA2B 4004/4885 |
| US-20250205219-A1 | TARGETED DEGRADATION OF VAV1 | VAV1, KRAS, CBL | PNMT 4106/4885ADRA2A 3731/4885ADRA2B 4004/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.